GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] can we stop arguing about half-life until somebody posts a number — 28 comments in the full submission. View in context.
638
c/glp1science·submitted 5 months ago by u/nhs_waitlist_n

[Discussion] can we stop arguing about half-life until somebody posts a number

Discussionbranch of 7 comments

Slightly embarrassed to be asking this, but: can we stop arguing about half-life until somebody posts a number. Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site. The GIP question, which is the most interesting unsettled thing in this field. Dual…

Read the full submission and all 28 comments →

This branch

7 comments, started 5 months ago
u/employer_carveout46 points·5 months ago

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

replysharereportpermalink
u/plain_titration34 points·5 months ago

What was the exposure in that experiment relative to therapeutic?

replysharereportpermalink
u/rina_bergstrom15 points·5 months ago

half-life is why these are weekly and not daily

replysharereportpermalink
u/nhs_waitlist_nOPUK11 points·5 months ago

receptor distribution is why the side effects are where they are

replysharereportpermalink
u/milan_mensah5 points·5 months ago

read the discussion section, that is where the honesty lives

replysharereportpermalink
u/brigade_detector5 points·5 months ago

dose response is not linear and nobody should assume it is

replysharereportpermalink
u/osman_eriksen2 points·5 months ago

dose response is not linear and nobody should assume it is

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →